| 8th Mar 2013 7:00 am |
RNS |
OML 40 Operational Update |
| 28th Jan 2013 4:12 pm |
RNS |
TR-1: Notification of major interest in shares |
| 28th Jan 2013 3:54 pm |
RNS |
Holding(s) in Company |
| 7th Jan 2013 7:00 am |
RNS |
OML 40 Production Update |
| 20th Dec 2012 8:37 am |
RNS |
Holding(s) in Company |
| 19th Dec 2012 7:00 am |
RNS |
Board Appointments and Director's Shareholding |
| 6th Nov 2012 4:58 pm |
RNS |
Holding(s) in Company |
| 26th Oct 2012 4:45 pm |
RNS |
Holding(s) in Company |
| 2nd Oct 2012 5:09 pm |
RNS |
Holdings in Company and Total Voting Rights |
| 28th Sep 2012 3:33 pm |
RNS |
Interim Results |
| 25th Sep 2012 6:00 pm |
RNS |
Holding(s) in Company |
| 11th Sep 2012 2:49 pm |
RNS |
Issue of Equity |
| 7th Sep 2012 10:56 am |
RNS |
Holding(s) in Company |
| 6th Sep 2012 5:56 pm |
RNS |
Holding(s) in Company |
| 5th Sep 2012 2:19 pm |
RNS |
Holding(s) in Company |
| 3rd Sep 2012 7:00 am |
RNS |
Admission to trading on AIM |
| 4th Aug 2009 3:59 pm |
RNS |
Holding(s) in Company |
| 30th Jul 2009 4:34 pm |
RNS |
Holding(s) in Company |
| 24th Jul 2009 5:09 pm |
BUS |
Director/PDMR Shareholding |
| 17th Jul 2009 5:58 pm |
RNS |
Directorate Change |
| 17th Jul 2009 5:57 pm |
BUS |
Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease |
| 16th Jul 2009 2:18 pm |
RNS |
Results of Annual General Meeting |
| 13th Jul 2009 11:30 am |
BUS |
Elan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid |
| 10th Jul 2009 4:59 pm |
RNS |
Cancellation of UK Listing |
| 8th Jul 2009 7:00 am |
BUS |
Elan Announces Webcast of Second Quarter 2009 Financial Results |
| 3rd Jul 2009 10:57 am |
RNS |
Block Listing Six Monthly Return |
| 2nd Jul 2009 12:57 pm |
RNS |
Holding in Company |
| 2nd Jul 2009 12:41 pm |
PRN |
Johnson & Johnson, Elan Announce Definitive Agreement |
| 1st Jun 2009 7:00 am |
BUS |
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy |
| 29th May 2009 4:36 pm |
RNS |
Price Monitoring Extension |
| 29th May 2009 2:00 pm |
BUS |
Renee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer |
| 29th May 2009 11:54 am |
BUS |
Total Voting Rights |
| 30th Apr 2009 12:16 pm |
BUS |
Total Voting Rights |
| 27th Apr 2009 3:35 pm |
RNS |
Annual Report |
| 14th Apr 2009 5:09 pm |
RNS |
Holding(s) in Company |
| 27th Feb 2009 2:44 pm |
BUS |
Total Voting Rights |
| 25th Feb 2009 12:23 pm |
BUS |
Director/PDMR Shareholding |
| 12th Feb 2009 6:00 pm |
BUS |
Director/PDMR Shareholding |
| 12th Feb 2009 6:00 pm |
BUS |
Director/PDMR Shareholding |
| 9th Feb 2009 7:00 am |
BUS |
MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology |
